- Home
- SXTC vs REVB Comparison
SXTC vs REVB Comparison
Compare SXTC & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXTC
- REVB
- Stock Information
- Founded
- SXTC 2005
- REVB 2020
- Country
- SXTC China
- REVB United States
- Employees
- SXTC N/A
- REVB N/A
- Industry
- SXTC Biotechnology: Pharmaceutical Preparations
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- SXTC Health Care
- REVB Health Care
- Exchange
- SXTC Nasdaq
- REVB Nasdaq
- Market Cap
- SXTC 1.6M
- REVB 1.4M
- IPO Year
- SXTC 2019
- REVB N/A
- Fundamental
- Price
- SXTC $0.34
- REVB $0.34
- Analyst Decision
- SXTC
- REVB
- Analyst Count
- SXTC 0
- REVB 0
- Target Price
- SXTC N/A
- REVB N/A
- AVG Volume (30 Days)
- SXTC 1.6M
- REVB 1.7M
- Earning Date
- SXTC 01-01-0001
- REVB 11-08-2024
- Dividend Yield
- SXTC N/A
- REVB N/A
- EPS Growth
- SXTC N/A
- REVB N/A
- EPS
- SXTC N/A
- REVB N/A
- Revenue
- SXTC $1,928,497.00
- REVB N/A
- Revenue This Year
- SXTC N/A
- REVB N/A
- Revenue Next Year
- SXTC N/A
- REVB N/A
- P/E Ratio
- SXTC N/A
- REVB N/A
- Revenue Growth
- SXTC N/A
- REVB N/A
- 52 Week Low
- SXTC $0.33
- REVB $0.32
- 52 Week High
- SXTC $6.39
- REVB $25.26
- Technical
- Relative Strength Index (RSI)
- SXTC 35.42
- REVB 27.29
- Support Level
- SXTC $0.33
- REVB $0.32
- Resistance Level
- SXTC $0.55
- REVB $0.47
- Average True Range (ATR)
- SXTC 0.05
- REVB 0.08
- MACD
- SXTC 0.00
- REVB -0.02
- Stochastic Oscillator
- SXTC 2.26
- REVB 3.40
About SXTC China SXT Pharmaceuticals Inc.
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).